# US 2023/0263771 A1 · Small molecules that treat or prevent viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263771 A1
- Document ID: US20230263771A1
- Status: Published application
- Kind: A1
- Application number: 18/111,210
- Filed: 2023-02-17
- Published: 2023-08-24
- Earliest claimed: 2022-02-21
- Assignees: University of Houston System
- Applicants: University of Houston System
- Inventors: Bradley K. McConnell; Arfaxad Reyes Alcaraz; John W. Craft; Robert J. Schwartz
- Web page: https://patentgrep.com/patent/US20230263771A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present disclosure pertain to anti-viral compounds suitable for use in blocking virus entry into cells. Further embodiments of the present disclosure pertain to methods of blocking virus entry into cells by associating the cells with at least one anti-viral compound of the present disclosure. In some embodiments, the associating occurs in vitro. In some embodiments, the associating occurs in vivo in a subject through administration of the at least one anti-viral compound to the subject. Additional embodiments of the present disclosure pertain to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound of the present disclosure. In some embodiments, the subject is a human being suffering from or vulnerable to the viral infection. In some embodiments, the virus includes a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2).

## Claims

### Claim 1

A method of treating or preventing a viral infection in a subject, said method comprising:
administering to the subject at least one compound, wherein the at least one compound is selected from the group consisting of:
and derivatives thereof,
wherein each of X1, X2, and X3 are independently selected from the group consisting of NH, NOH, NO2H, POH, PO2H, CO, CCl2, CBr2, CF2, O, S, and CH2, and
wherein each of R1 and R2 are independently selected from the group consisting of H, CCl3, CHCl2, CH2Cl, CF3, CHF2, CH2F, CH3, alkyl groups, alkoxy groups, amine groups, carboxyl groups, aldehyde groups, ester groups, phenyl groups, silyl hydrides, silyl chlorides, silyl fluoride, silyl bromide, silyl ethers, silanols, siloles, derivatives thereof, and combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein X1 is NH, X2 is CO, and X3 is O.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound comprises a structure selected from the group consisting of:
and derivatives thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound comprises the following structure:

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is in a composition.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition is in a form selected from the group consisting of nasal sprays, aerosols, eye drops, injectable suspensions, tablets, or combinations thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein the composition is in an aerosol form.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administering occurs by a method selected from the group consisting of oral administration, inhalation, subcutaneous administration, intravenous administration, intraperitoneal administration, intramuscular administration, intrathecal injection, intra-articular administration, topical administration, central administration, peripheral administration, aerosol-based administration, nasal administration, transmucosal administration, transdermal administration, parenteral administration, direct administration into airway epithelial cells, and combinations thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the administration comprises nasal administration.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administration comprises aerosol-based administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the administration comprises direct administration into airway epithelial cells.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a human being.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is suffering from the viral infection.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is vulnerable to the viral infection.

### Claim 15 (depends on 1)

The method of claim 1, wherein the method is utilized to prevent the virus from infecting the subject.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method is utilized to treat the subject from an infection by the virus.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method is utilized to treat and prevent the viral infection.

### Claim 18 (depends on 1)

The method of claim 1, wherein the virus causing the viral infection comprises a virus containing a Spike protein, a cell entry protein that binds to the at least one compound, or combinations thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the virus causing the viral infection comprises a coronavirus, an influenza virus, a retrovirus, a lentivirus, or combinations thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the virus causing the viral infection comprises a coronavirus selected from the group consisting of severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome-related coronavirus (SARSr-CoV), human coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome-related coronavirus 1 (SARS-CoV-1), severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), or combinations thereof.
